{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=quinolone&page=7",
    "query": {
      "intervention": "quinolone",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 629,
    "total_pages": 63,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=quinolone&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=quinolone&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-12T20:12:41.883Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05988034",
      "title": "A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Electrocardiography"
      ],
      "interventions": [
        {
          "name": "Avacopan",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Placebo for avacopan",
          "type": "DRUG"
        },
        {
          "name": "Placebo for moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 58,
      "start_date": "2019-11-08",
      "completion_date": "2020-03-31",
      "has_results": false,
      "last_update_posted_date": "2023-08-14",
      "last_synced_at": "2026-11-12T20:12:41.883Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05988034"
    },
    {
      "nct_id": "NCT00721344",
      "title": "A Study to Determine if Technosphere® Inhalation Powder (FDKP) Causes ECG Changes (QTc) Following the Medication's Inhaled Administration.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "Technosphere Inhalation Powder (FDKP)",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mannkind Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 48,
      "start_date": "2008-04",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2012-06-13",
      "last_synced_at": "2026-11-12T20:12:41.883Z",
      "location_count": 1,
      "location_summary": "Tacoma, Washington",
      "locations": [
        {
          "city": "Tacoma",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00721344"
    },
    {
      "nct_id": "NCT05716854",
      "title": "Electrophysiological Effects of Potential QT Prolonging Drugs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Drug-induced QT Prolongation",
        "Pharmacokinetics",
        "Pharmacodynamics"
      ],
      "interventions": [
        {
          "name": "Clarithromycin",
          "type": "DRUG"
        },
        {
          "name": "Pimozide",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Part 1)",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Cobicistat",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin and Cobicistat",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Part 2)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Food and Drug Administration (FDA)",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 44,
      "start_date": "2023-03-21",
      "completion_date": "2023-06-13",
      "has_results": false,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-11-12T20:12:41.883Z",
      "location_count": 1,
      "location_summary": "West Bend, Wisconsin",
      "locations": [
        {
          "city": "West Bend",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05716854"
    },
    {
      "nct_id": "NCT02087579",
      "title": "Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Psychotic Disorders",
        "Schizophrenia",
        "Bipolar Disorder",
        "Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Aripiprazole, oral formulation",
          "type": "DRUG"
        },
        {
          "name": "Olanzapine, oral formulation",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone, oral formulation",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone, LAI",
          "type": "DRUG"
        },
        {
          "name": "Quetiapine, oral formulation",
          "type": "DRUG"
        },
        {
          "name": "Risperidone, oral formulation",
          "type": "DRUG"
        },
        {
          "name": "Risperidone, LAI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 305,
      "start_date": "2014-02",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2015-10-29",
      "last_synced_at": "2026-11-12T20:12:41.883Z",
      "location_count": 6,
      "location_summary": "Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Hoffman Estates",
          "state": "Illinois"
        },
        {
          "city": "Cedarhurst",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02087579"
    },
    {
      "nct_id": "NCT06258265",
      "title": "A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "TAK-279",
          "type": "DRUG"
        },
        {
          "name": "TAK-279 Placebo",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 120,
      "start_date": "2024-04-29",
      "completion_date": "2024-07-09",
      "has_results": false,
      "last_update_posted_date": "2024-07-11",
      "last_synced_at": "2026-11-12T20:12:41.883Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06258265"
    },
    {
      "nct_id": "NCT00468130",
      "title": "Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Autism"
      ],
      "interventions": [
        {
          "name": "Aripiprazole",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Medicine and Dentistry of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 13,
      "start_date": "2006-05",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2022-01-14",
      "last_synced_at": "2026-11-12T20:12:41.883Z",
      "location_count": 1,
      "location_summary": "Piscataway, New Jersey",
      "locations": [
        {
          "city": "Piscataway",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00468130"
    },
    {
      "nct_id": "NCT00556140",
      "title": "The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psychotic Depression"
      ],
      "interventions": [
        {
          "name": "Aripiprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 16,
      "start_date": "2003-06",
      "completion_date": "2008-01",
      "has_results": true,
      "last_update_posted_date": "2012-08-20",
      "last_synced_at": "2026-11-12T20:12:41.883Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00556140"
    },
    {
      "nct_id": "NCT05294588",
      "title": "Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gonorrhea Male"
      ],
      "interventions": [
        {
          "name": "Cefixime",
          "type": "DRUG"
        },
        {
          "name": "Ceftriaxone",
          "type": "DRUG"
        },
        {
          "name": "Ciprofloxacin",
          "type": "DRUG"
        },
        {
          "name": "Neisseria gonorrhoeae strain FA1090",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Meningococcal Group B Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tetanus-diptheria Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "MALE",
        "summary": "18 Years to 35 Years · Male only"
      },
      "enrollment_count": 65,
      "start_date": "2022-04-18",
      "completion_date": "2026-02-05",
      "has_results": false,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-11-12T20:12:41.883Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05294588"
    },
    {
      "nct_id": "NCT01498861",
      "title": "Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Ortho-Cyclen",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 16,
      "start_date": "2011-12",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2012-05-21",
      "last_synced_at": "2026-11-12T20:12:41.883Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01498861"
    },
    {
      "nct_id": "NCT01461460",
      "title": "A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "TR-701 FA 1200 mg",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin 400 mg",
          "type": "DRUG"
        },
        {
          "name": "TR-701 FA 200 mg plus Placebo",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 48,
      "start_date": "2011-11-28",
      "completion_date": "2011-12-23",
      "has_results": false,
      "last_update_posted_date": "2018-12-05",
      "last_synced_at": "2026-11-12T20:12:41.883Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01461460"
    }
  ]
}